VRCA

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) is a dermatology-focused biotechnology company founded in 2013 and headquartered in West Chester, Pennsylvania. The company went public in June 2018 and specializes in developing and commercializing treatments for various skin diseases. Verrica's primary focus is on cantharidin-based therapies, with its lead product YCANTH being the first and only FDA-approved treatment for molluscum contagiosum, a common viral skin infection primarily affecting children. The company has evolved from a pure development-stage biotech to a commercial-stage pharmaceutical company with an expanding product pipeline targeting multiple dermatological conditions.